Marketing - Press Releases

Date	Title	Company
12-Dec-2019	Clevegen downregulates a range of major immuno-oncology (IO) checkpoints in MATINS cancer patients Biomarker analysis could guide future combination therapies with Clevegen	Faron Pharmaceuticals Oy
11-Dec-2019	Dr Samareh Lajaunias, Director at Combioxin Speaking at SMi's 22nd Annual Superbugs & Superdrugs Conference	SMi Group
11-Dec-2019	Invite from Lynne Ensor chair for Pharma Microbiology East Coast Conference, April 2020, Boston	SMi Group
10-Dec-2019	Stilla Technologies Names Key Leadership Slate to Support Global Growth of its Next-Generation Digital PCR Solution	Stilla Technologies
10-Dec-2019	Peregrine Ventures Raises $115 Million for its Fourth Fund Bringing Total Managed Funds and Co-Invest Capital to $400 Million	Peregrine
10-Dec-2019	Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion	Sanofi
10-Dec-2019	Vaccine Regimen from Janssen and Bavarian Nordic to Support Republic of Rwanda’s Preparedness Against Ebola Outbreak	Bavarian Nordic
10-Dec-2019	bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin™ Gene Therapy for Sickle Cell Disease (SCD) at 61st ASH Annual Meeting and Exposition	bluebird bio, Inc
10-Dec-2019	Autolus Therapeutics Announces New Data Showcasing Clinical Progress of AUTO3 in B Cell Malignancies	Autolus Therapeutics plc
10-Dec-2019	KITE, A GILEAD COMPANY, ANNOUNCES LONG-TERM DATA FROM ZUMA-1 SHOWING 47% OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA PATIENTS WERE ALIVE THREE YEARS AFTER YESCARTA® (AXICABTAGENE CILOLEUCEL) TREATMENT	Kite, a Gilead Company
10-Dec-2019	Autolus Therapeutics Announces New Data Showcasing Clinical Progress of Programmed T Cell Therapy Pipeline in Blood Cancers	Autolus Therapeutics plc
10-Dec-2019	XBiotech Announces Agreement to Sell True Human Antibody Bermekimab Targeting IL-1a to Janssen	XBiotech
10-Dec-2019	Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis	Galderma
10-Dec-2019	Abeona Therapeutics Cleared to Initiate Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa	Abeona Therapeutics Inc
10-Dec-2019	Acalabrutinib (Calquence) significantly prolonged the time patients lived without disease progression or death in previously untreated chronic lymphocytic leukaemia	AstraZeneca
10-Dec-2019	Upperton is Launching an Enabling Technology Screening Protocol	Upperton Pharma Solutions
10-Dec-2019	Precipice Design Reimagines NIOX VERO® Asthma Detection and Management System	Precipice Design
10-Dec-2019	bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition	Bristol-Myers Squibb
10-Dec-2019	Genmab Achieves USD 100 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen	Genmab A/S
09-Dec-2019	The Alliance for Regenerative Medicine to host European ATMP Access Meeting in Brussels	The Alliance for Regenerative Medicine